CRISPR THERAPEUTICS AG Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
CRISPR THERAPEUTICS AG (CRSP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $66.24 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-03
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $65.59, a 11.47% increase year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $58.84, a 17.36% decline year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $71.20, a 17.32% decline year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $86.12, a 9.73% increase year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $65.74, a 5.98% decline from fiscal 2024.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $69.92, a 15.60% decline from fiscal 2023.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $82.84, a 2.69% decline from fiscal 2022.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $85.13, a 7.03% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $66.24 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | $65.59 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $65.74 10-K · filed 2026-02-12 | |||
| 2025-09-30 | $65.18 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $62.22 10-Q · filed 2025-08-04 | |||
| 2025-03-31 | $58.84 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $69.92 10-K · filed 2025-02-11 | |||
| 2024-09-30 | $75.21 10-Q · filed 2024-11-05 | |||
| 2024-06-30 | $72.96 10-Q · filed 2024-08-05 | |||
| 2024-03-31 | $71.20 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $82.84 10-K · filed 2024-02-21 | |||
| 2023-09-30 | $86.14 10-Q · filed 2023-11-06 | |||
| 2023-06-30 | $86.70 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $86.12 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $85.13 10-K · filed 2023-02-21 | |||
| 2022-09-30 | $82.40 10-Q · filed 2022-11-01 | |||
| 2022-06-30 | $76.85 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $78.48 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $79.54 10-K · filed 2022-02-15 | |||
| 2021-09-30 | $65.84 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | $54.14 10-Q · filed 2021-07-29 | |||
| 2021-03-31 | $43.31 10-Q · filed 2021-04-27 | |||
| 2020-12-31 | $41.61 10-K · filed 2021-02-16 | |||
| 2020-09-30 | $41.35 10-Q · filed 2020-10-28 | |||
| 2020-06-30 | $42.12 10-Q · filed 2020-07-27 | |||
| 2020-03-31 | $42.20 10-Q · filed 2020-04-28 | |||
| 2019-12-31 | $35.35 10-K · filed 2020-02-12 | |||
| 2019-09-30 | $31.50 10-Q · filed 2019-10-28 | |||
| 2019-06-30 | $33.48 10-Q · filed 2019-07-29 | |||
| 2019-03-31 | $39.57 10-Q · filed 2019-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |